Equities research analysts at StockNews.com assumed coverage on shares of Corbus Pharmaceuticals (NASDAQ:CRBP – Get Free Report) in a research note issued on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
Separately, Oppenheimer reiterated an “outperform” rating and issued a $22.00 price target on shares of Corbus Pharmaceuticals in a research note on Wednesday, August 9th.
Corbus Pharmaceuticals Price Performance
Institutional Trading of Corbus Pharmaceuticals
A number of institutional investors and hedge funds have recently bought and sold shares of CRBP. Renaissance Technologies LLC increased its holdings in Corbus Pharmaceuticals by 371.0% in the first quarter. Renaissance Technologies LLC now owns 1,157,191 shares of the biopharmaceutical company’s stock valued at $615,000 after purchasing an additional 911,491 shares during the period. Two Sigma Investments LP grew its stake in shares of Corbus Pharmaceuticals by 366.7% in the 4th quarter. Two Sigma Investments LP now owns 570,168 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 448,002 shares during the period. Sio Capital Management LLC acquired a new stake in shares of Corbus Pharmaceuticals in the 1st quarter valued at about $1,090,000. Vident Investment Advisory LLC grew its stake in shares of Corbus Pharmaceuticals by 66.2% in the 1st quarter. Vident Investment Advisory LLC now owns 255,146 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 101,659 shares during the period. Finally, State Street Corp grew its stake in shares of Corbus Pharmaceuticals by 10.7% in the 1st quarter. State Street Corp now owns 395,513 shares of the biopharmaceutical company’s stock valued at $210,000 after buying an additional 38,304 shares during the period. 16.73% of the stock is currently owned by institutional investors and hedge funds.
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, an endocannabinoid small molecule drug for the treatment of obesity and related metabolic diseases; and lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial or the treatment of inflammation and fibrosis.
- Five stocks we like better than Corbus Pharmaceuticals
- What Are Meme Stocks and Are They Viable Investments?
- Analyst says Archer Aviation may double. Is it time to buy?
- How to Analyze Restaurant Stocks
- Alibaba’s bottom is in: Analysts see a monster rally ahead
- Best Restaurant Stocks to Invest in Now
- TripAdvisor is on AI-powered recovery from record lows
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.